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The aim of this study was to evaluate Exendin-4 (EX-4) effects on islet volume and number in the mouse 
pancreas. Thirty-two healthy adult male NMRI mice were randomly divided into control and experimental 
groups. EX-4 was injected intraperitoneally (i. p.) at doses of 0.25 (E1 group), 0.5 (E2 group), and 1 μg/kg 
(E3 group), twice a day for 7 consecutive days. One day after the final injection, the mice were sacrificed, 
and the pancreas from each animal dissected out, weighed, and fixed in 10% formalin for measurement 
of pancreas and islet volume, and determination of islet number by stereological assessments. There was 
a significant increase in the weight of pancreases in the E3 group. Islet and pancreas volumes in E1 and 
E2 groups were unchanged compared to the control group. The E3 group showed a significant increase 
in islet and pancreas volume (P < 0.05). There were no significant changes in the total number of islets 
in all three experimental groups. The results revealed that EX-4 increased pancreas and islet volume in 
non-diabetic mice. The increased total islet mass is probably caused by islet hypertrophy without the 
formation of additional islets.
Uniterms: Exendin-4/effects/experimental study. Pancreas/effects fo Exendin-4. Islet/hypertrophy. 
Stereology. 
O objetivo deste estudo foi avaliar os efeitos do Exendin-4 (EX-4) sobre o volume e número de ilhotas 
no pâncreas. Trinta e dois camundongos NMRI machos saudáveis e adultos foram divididos ao acaso 
em grupos controle e grupos experimentais. EX-4 foi injetado intraperitonealmente (i. p.) nas doses de 
0,25 (grupo E1), 0,5 (grupo E2) e 1 (grupo E3), duas vezes por dia durante 7 dias consecutivos. Um 
dia após a injeção final, os camundongos foram sacrificados e o pâncreas de cada animal foi dissecado, 
pesado e fixado em solução de formaldeído 10% para avaliação do volume do pâncreas e ilhotas e do 
número de ilhotas por métodos estereológicos. Observou-se aumento significativo no peso de pâncreas 
no grupo E3. O volume do pâncreas assim como das ilhotas não apresentou alterações nos grupos E1 
e E2, quando comparados ao grupo controle No grupo E3 houve aumento significativo no volume do 
pâncreas e das ilhotas (P<0,05). Não se observaram alterações significativas no número de ilhotas nos 
três grupos experimentais. Os resultados revelaram que o EX-4 provoca aumento no volume do pâncreas, 
bem como no volume das ilhotas em camundongos não-diabéticos. O aumento no volume total de ilhotas 
deve-se, provavelmente, a hipertrofia das ilhotas sem a formação de ilhotas adicionais.
Unitermos: Exendina-4/efeitos/estudo experimental. Pâncreas/efeito do Exendina-4. Ilhotas/hipertrofia. 
Estereologia.
INTRODUCTION 
Glucagon-like peptide-1 (GLP-1) is a peptide 
secreted from the gut in response to food. It acts directly 
on β cells, enhancing the effect of glucose in stimulating 
insulin secretion from these cells. When administered 
to diabetic mice, GLP-1 lowers blood glucose levels 
and stimulates insulin secretion (Xu et al., 1999). In 
addition, GLP-1 increases the β-cell mass by inducing the 
differentiation and neogenesis of ductal progenitor cells 
into islet endocrine cells (Hui et al., 2001; Abraham et al., 
2002). In a previous in vitro study, was shown that GLP-
1 is capable of enhancing fetal pig β-cell differentiation 
from progenitor epithelial cells as well as initiating their 
functional maturation in islet-like cell clusters (Hardikar 
et al., 2002).
Exendin-4, a long-acting GLP-1 receptor (GLP-1R) 
agonist, binds to and activates the GLP-1R with the same 
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potency as GLP-1 (Xu et al., 1999). Exendin-4 (EX-4) is 
resistant to the enzyme dipeptidyl peptidase 4 (DPT-IV), 
which is present in serum. GLP-1 is rapidly metabolized 
by DPP-IV (Kieffer et al., 1995). It has been reported 
previously that EX-4 is capable of stimulating both the 
differentiation of β cells from ductal progenitor cells and 
proliferation of β cells when given to rats and human 
(Zhou et al., 1999; Stoffers et al., 2000; Kastin et al., 
2003).
Previous studies on EX-4 action were mostly 
performed in diabetic rodent models. However, some 
studies demonstrate that EX-4 has a beneficial effect 
in non-diabetic animals. It has been reported that EX-4 
causes weight loss (De Fronzo et al., 2005; Buse et al., 
2004; Kendall et al., 2005). In the placebo-controlled 
component of the pivotal trials, which lasted 30 weeks, 
mean weight reduction ranged from between 1 and 3 kg 
compared with placebo. In open-label extensions, weight 
continued to decline over 2 years of treatment, by up to 
5 kg from baseline (Blonde et al., 2006; Buse et al., 2007).
It is known that EX-4 can pass through the blood–
brain barrier (Kastin et al., 2003) and exert central effects, 
including promotion of neurotrophic or neuroprotective 
actions (Perry et al., 2000a; Perry et al., 2000b) and 
enhancement of cognitive functions (During et al., 2003). 
These findings suggest that GLP-1 receptor stimulation 
in the central nervous system plays a critical role in 
regulating neuronal plasticity and cell survival. Vella et 
al. (2003) reported that EX-4 and GLP-1 increase cortisol 
secretion in human subjects. However, neither of these 
alter insulin action in non-diabetic human subjects (Vella 
et al., 2003). Ranta et al. (2006) demonstrated that EX-4 
protects against glucocorticoid-induced mouse beta-cells 
or INS-1 cell apoptosis. Chen et al. showed that EX-4 
can inhibit rat cardiomyocyte apoptosis early after scald 
injury possibly by suppressing caspase-3 activity in the 
myocardium.
In spite of numerous experimental studies about 
EX-4 effects on various tissues in non-diabetic subjects, 
only one study has investigated its effects on the pancreas 
(Nachnani et al., 2010). In the present study, the effect of 
EX-4 on islet volume and number in the mouse pancreas 
was investigated by using stereological procedures.
MATERIAL AND METHODS
Animals
In this study, 32 healthy adult male NMRI (Naval 
Medical Research Institute) mice (6–8 weeks old, 25-30 g) 
were used. The animals were obtained from Ahvaz 
Jundishapur University of Medical Sciences, Experimental 
Research Center. This study was approved by the 
research ethics committee of Jundishapur University 
and carried out in an ethically proper way by following 
the guidelines provided. The animals were kept under 
standard laboratory conditions (12h-dark and 12 h-light 
cycle, relative humidity of 50 ± 5% and 22 ± 3 °C) for at 
least 1 week before the experiment and these conditions 
were maintained until the end of the experiment. Animal 
cages were kept clean, and commercial food (pellet) and 
water were provided ad libitum.
Experimental design
The mice were randomly divided into control 
and experimental groups, all of which contained eight 
animals. EX-4 (Sigma) was dissolved in distilled water 
and injected intraperitoneally (i.p.) at doses of 0.25 (E1 
group), 0.5 (E2 group), and 1 μg/kg (E3 group), twice a 
day for 7 consecutive days. The dosage and duration of 
treatment with EX-4 was selected according to previous 
studies that demonstrated the beneficial effect of EX-4 on 
focal cerebral ischemia-induced infarction in rats (Briyal 
et al., 2012). One day after the final injection, the mice 
were sacrificed by cervical dislocation, and the pancreas 
from each animal was dissected out, weighed, and fixed 
in 10% formalin. 
Stereological assessments
Histology and sampling of sections 
Each pancreas was embedded randomly in paraffin 
and sectioned exhaustively into 5µm-thick sections. Figure 
1 illustrates the sampling of sections. Three sections 
were collected onto each glass slide. With a random start 
point among the first 40 sections, every 40th section was 
sampled (the primary sections). In addition, two sections 
ahead of each primary section were sampled as the 
reference section. Because every section was 5 µm thick, 
it follows that there was 200 µm between the primary 
sections and 10 µm between a primary section and the 
corresponding reference section. All primary and reference 
sections were stained with hematoxylin and eosin (H & E).
Microscopes and equipment
The sections were analyzed at 400× magnification 
by an MP3, Nr 3437 microscope (PZO, Poland) equipped 
with a projecting arm to project the image onto a monitor 
attached to the microscope. The applied probes used for 
the stereological examinations (point-counting grid or 
counting frame as described below) were superimposed 
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onto the monitor so that the microscope projected the 
image onto the grid. We used two microscopes at the same 
time for counting the total number of islets in primary and 
reference sections.
Total volumes of islets and pancreas 
Using step-lengths of 950 µm in the x-direction 
(Δx) and 750 µm in the y-direction (Δy), all primary 
sections from each pancreas were systematically 
examined. A point-counting grid with 108 points, 1 
of them encircled, was applied (Figure 2-A). Moving 
through all primary sections from the pancreata, the 
number of times 1 of the 108 points hit an islet was 
counted. An islet was defined as a cluster of cells with a 
minimum of three visible nuclei displaying the normal 
characteristics of islet endocrine cells (pale cytoplasm 
with approximately spherical nuclei). Simultaneously, 
the number of times the encircled point hit pancreatic 
tissue (exocrine pancreatic tissue, ducts, vessels, islets, 
etc.) was counted. The values for the total volume 
of pancreas and the islets of Langerhans were then 
calculated based on the Cavalieri principle (Gundersen 
et al., 1987; Bock et al., 2003).
1) V (pan) = a/p (pan) × N (p - p) × T × ∑P (pan)
                   = 0.1425 mm3 × ∑P (pan) 
where V (pan) is the total volume of pancreas, a/p(pan) is 
the area per point (in this case Δx× Δ y because only one 
point in the grid was used to count points that hit pancreas), 
N (p – p) is the number of sections between the primary 
sections (50 sections in this case), T is the section thickness 
(5 μm), and ∑P(pan) is the total number of points that hit 
pancreas.
2) V (isl) = a/p (isl) × N (p - p) × T × ∑P (isl)
                 = 1.319 × 103 mm3 × ∑P (isl)
where V (isl) is the total volume of islets, a/p (isl) is the 
area per point (in this case Δx × Δ y /99 because there were 
99 points in the grid used to count points that hit islets), 
and ∑P (isl) is the total number of points that hit the islets.
Tissue shrinkage influences all stereologic size 
estimators whether distance, surface area, or volume. 
There is no exact unbiased way to obtain information about 
tissue deformation during tissue fixation and processing. 
The area of a piece of pancreas tissue before and after 
fixation/processing may be estimated, and the tissue 
shrinkage can be calculated as (Nyengaard, 1999):
Total number of islets
In another session, the sampling within the primary 
sections was performed, but an unbiased counting frame 
FIGURE 1- Sampling method of histological sections is shown.
FIGURE 2 - Point counting grade (A) and unbiased counting 
frame (B).
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(Figure 2-B) was attached to the monitor. The rules of 
the counting frame define objects completely outside the 
frame or objects that touch the exclusion lines (the full 
lines in Figure 2) as being outside the frame, whereas 
objects that are completely within the frame or touch 
only the inclusion lines (the dashed lines in Figure 2) 
are defined as being within the frame. We applied the 
dissector principle (Sterio, 1984) to count the islets. 
Whenever an islet profile was sampled by the counting 
frame, the corresponding position in the reference section 
was located with the other microscope, and it was then 
determined whether the islet was also visible in the 
reference section. An islet was counted if it appeared 
in the primary section but not in the reference section. 
Because the sampling of sections, as well as the within 
section sampling, were performed with known sampling 
fractions, the total number of islets can be calculated 
according to the fractionator principle (Bock et al., 
2003; Gundersen et al., 1987) from:
where N (isl) is the total number of islets in the pancreas, 
N (p – p) is the number of sections between the primary 
sections, N (p – r) is the number of sections between a 
primary section and the corresponding reference section 
(two in this case), Δ x and Δ y are the step lengths, 
A(frame) is the area of the counting frame corrected for 
magnification (412.674 μm2), and ∑Q- (isl) is the total 
number of islets counted in one pancreas (Bock et al., 
2003).
RNA preparation and Reverse Transcription Polymerase 
Chain Reaction (RT-PCR)
Isolated pancreases were either used immediately 
or snap frozen in liquid nitrogen and stored at −80 °C 
until use. Using the RNeasy Mini kit (Qiagen), RNA was 
isolated from the tissues according to manufacturer’s 
instructions. RT-PCR was performed using a One Step 
RT-PCR kit (Qiagen) which contains reverse transcriptase 
to synthesize cDNA from the RNA isolated and DNA 
polymerase for the PCR. RT-PCR conditions consisted of 
a 30 min step at 50 °C to allow the reverse transcriptase 
activity followed by 15 min at 95 °C to deactivate the 
reverse transcriptase and activate the Taq polymerase 
present in the enzyme mixture. The PCR process consisted 
of 6 s at 94 °C (denaturing step), 30 s at the annealing 
temperature (55 °C), and a 45 s step at 72 °C for extension, 
with all steps being repeated for 30 cycles. A final 
extension step lasted 10 min at 72 °C.
P r i m e r  s e q u e n c e s  w e r e  a s  f o l l o w s  w i t h 
the expected product length: Glut-2, sense 5’ CA
GCTGTCTCTGTGCTGCTTGT3’ ,ant i sense  5’ 
GCCGTCATGCTCACATAACTCA3’ (150 bp); Insulin, 
sense 5’ TCTTCTACACACCCATGTCCC 3’, antisense 
5’ GGTGCAGCACTGATCCAC 3’, (149 bp); and 
GAPDH, sense 5’ CTC TGGTGGACCTCATGGCCTAC 
3’, antisense 5’ CAGCAACTGAGGGCCTCTCT 3’ (105 
bp) was used as the house keeping gene (Sun et al., 2007).
Statistical analysis
The data were analyzed using one-way ANOVA 
followed by the Post hoc LSD test and expressed as mean 
± SD. P < 0.05 was considered significant.
RESULTS
As expected, mean body weight was equal in the 
four groups. Weight of pancreases in E1 and E2 groups 
were similar to the control group. There was a significant 
increase in the relative pancreas weight / body weight in 
the E3 group (Figure 3).
The present study confirms a 30% tissue shrinkage 
in paraffin embedding. This shrinkage considered when 
the final results were reported.
In the E1 group, total islet volume and total pancreas 
volume were similar to the control group. Total islet 
numbers were also similar to the control group. Pancreas 
tissue showed normal architecture.
In the E2 group, total islet volume and total 
pancreas volume were slightly increased (P > 0.05). 
Total islet numbers were similar to the control group. No 
histopathological changes were observed in this group.
In the E3 group, total pancreas volume was 
significantly higher than the control group (P < 0.05). Total 
FIGURE 3- Relative pancreas weight / body weight in control 
and experimental groups. Values expressed as means ± SD for 
8 mice. * P < 0.05 compared to control group.
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islet volume was significantly increased compared to the 
control group (P < 0.05). Total islet numbers were similar 
to the control group. No histopathological changes were 
observed in this group. The results for total islet volume, 
total pancreas volume, and total islet numbers are depicted 
in Figure 4.
To determine whether EX-4 affects β-cell islet 
function, the expression of Glut-2 and insulin genes were 
assessed using RT-PCR. As illustrated in Figure 5, high 
expression of Glut-2 and insulin was detected in EX-4-
treated mice. Expression of these genes was markedly 
higher in E2 and E3 groups compared to control and E1 
groups.
FIGURE 4 - Total pancreas volume, total islet volume and 
total islet number of control and experimental groups. Values 
expressed as means ± SD for 8 mice. * P < 0.05 compared to 
control group.
FIGURE 5 - The expression of insulin and Glut-2 genes in 
various groups by RT-PCR method is shown.
DISCUSSION
Based on stereological methods ( such as 
fractionator sampling and dissector counting), we found 
an increase in the total volume of islets in the experimental 
groups, whereas the total number of islets was equal in the 
four groups with a reasonably narrow confidence interval 
for the difference in means.
The importance of GLP-1 for stimulation of islet 
cell proliferation was originally demonstrated in lean 
20-day-old normoglycemic mice (Edvell et al., 1999). 
Afterwards, several studies using in vivo models showed 
that GLP-1 can regulate islet growth mainly by controlling 
β-cell neogenesis (Xu et al., 1999; Stoffers et al., 2000; 
Perfetti et al., 2000; Tourrel et al., 2001; Tourrel et al., 
2002). Park et al. showed that EX-4 and exercise promotes 
beta-cell function and mass in islets of diabetic rat. Xu et 
al. have also reported that EX-4 increases β-cell mass. Fan 
et al. (1999) reported that EX-4 improves blood glucose 
control in both young and aging normal non-diabetic 
mice. The authors showed that EX-4 treatment improved 
glycemic control in both 3-month and 20 to 22-month-old 
mice. In both groups of mice, the blood glucose lowering 
effect was independent of beta cell function as indicated 
by unchanged beta cell proliferation, insulin secretion 
or beta cell mass. However, high expression of Insulin 2 
and Glut-2 genes in EX-4-treated cells was shown in the 
present study. In pancreatic β-cells, the glucose uptake is 
controlled by Glut-2, which is essential in the mechanism 
of glucose-induced insulin secretion (Olson et al., 1996). 
Glut-2 is the glucose sensor of β cells that leads to the 
production of insulin (Lopes Da Costa et al., 2004). 
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GLP-1 increases insulin secretion and the biosynthesis of 
important β-cell products besides insulin: glucokinase and 
Glut-2 glucose transporters (Verspohl et al., 2009). The 
increase in expression of these genes probably induces 
abnormally elevated secretion of insulin and causes 
hypoglycemia in non-diabetic animals.
As mentioned above, in this study the volume of 
islets was higher in EX-4-treated mice. One mechanism 
responsible for the expansion of islet mass is inhibition of 
apoptosis (Chen et al., 2011; Farilla et al., 2003; Kwon et 
al., 2009). It has also been shown that human islets treated 
with GLP-1 have a down-regulation of caspase-3 at the 
levels of mRNA of the active protein and up-regulation 
of the anti-apoptotic protein Bcl-2 (Farilla et al., 2003). A 
second mechanism responsible for the expansion of β-cell 
mass is enhanced cell proliferation or neogenesis.
Tourrel et al., by using a recognized model of 
β-cells regeneration (neonatalWistar rats injected with 
streptozotocin, so-called n0-STZ), showed that GLP-1 and 
Exendin-4, applied during the neonatal period, strongly 
stimulated β-cell regeneration mainly by β-cell neogenesis 
(Tourrel et al., 2001). Furthermore, treatment of diabetic 
Goto-Kakizaki (GK) rats with GLP-1 or Exendin-4 from 
day 2 to day 6 after birth resulted in stimulation of β-cell 
neogenesis and proliferation with persistent expansion of 
β-cell mass detected at adult age (Tourrel et al., 2002). 
However, the present study revealed that EX-4 caused no 
change in the number of islets. This indicates that EX-4 
has no neogenesis effects on islet cells in non-diabetic 
adult animals.
It has been stated in a literature review that new islets 
do develop under certain experimental conditions, such 
as after partial pancreatectomy, where the formation of 
new islets has been clearly demonstrated (Nachnani et 
al., 2010). Other anatomical structures, such as kidney 
glomeruli, also lack the ability of hyperplasia and instead 
become hypertrophic with an increased demand, probably 
because of the highly specific structure of the neurovascular 
and tubular systems necessary for appropriate function. 
Possibly, the architecture (i.e., the intra-islet vascular 
structure) of the islets is complex to such a degree that it 
only allows new islets to be formed during the formation, 
growth, or regeneration of the pancreas during fetal life or 
after partial pancreatectomy (Bock et al., 2003).
Nachnani et al. evaluated the histological and 
biochemical effects of EX-4 on the pancreas in rats. They 
showed that animals treated with Exendin-4 had pancreatic 
acinar inflammation, pyknotic nuclei and weighed 
significantly less than control rats. However, in the present 
study no evidence of pancreatic acinar inflammation or 
histopathological changes were observed.
CONCLUSION 
In this study, we demonstrated that EX-4 increased 
pancreas and islet volume in non-diabetic mice. The 
increased total islet mass is probably caused by islet 
hypertrophia without the formation of additional islets. 
This study also revealed that EX-4 can enhance the 
expression of insulin and Glut-2 genes, where this may induce 
hypoglycemia in non-diabetic mice. Further experiments are 
needed to clarify the exact mechanism of islet hypertrophy 
induced by EX-4 and other GLP-1 agonists.
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